C. diff Treatment: Oral Vancomycin, Fidaxomicin, and Bezlotoxumab

  1. Why Metronidazole Is No Longer First-Line
  2. Oral Vancomycin: How and Why It Works
  3. Fidaxomicin (Dificid): The Gut-Sparing Alternative
  4. Tapering and Pulsed Vancomycin for Recurrent CDI
  5. Bezlotoxumab (Zinplava): Blocking Toxin B to Prevent Recurrence
  6. Rifaximin Chaser After Vancomycin
  7. Managing First and Second Recurrences
  8. Surgical Management for Severe and Fulminant CDI
  9. Key Research Papers
  10. Connections
  11. Featured Videos

Why Metronidazole Is No Longer First-Line

For two decades, metronidazole was the go-to treatment for mild Clostridioides difficile infection (CDI). It was cheap, widely available, and appeared to work — at least in older, smaller studies. But as the evidence base grew, a troubling pattern emerged: metronidazole simply did not measure up to oral vancomycin, especially when patients were sicker.

Three randomized controlled trials drove the guideline change. Zar et al. (2007) randomized 150 patients with mild or severe CDI to oral metronidazole or oral vancomycin. In mild disease, cure rates were similar. In severe disease, vancomycin crushed metronidazole: 97% clinical cure versus 76% — a 21-percentage-point difference that is clinically enormous. Johnson et al. (2014) confirmed it in two large multinational trials, finding clinical cure rates 10–15 percentage points higher with vancomycin. The pattern was consistent: metronidazole is particularly weak in severe disease, in older patients, and in those with low albumin.

Both the 2017 and 2021 IDSA/SHEA guidelines removed metronidazole from the first-line recommendation entirely. Metronidazole may still be used when vancomycin and fidaxomicin are genuinely unavailable — a narrow and uncommon situation in most healthcare settings. Its failure is partly explained by pharmacokinetics: as colonic inflammation resolves, metronidazole absorption from the gut improves, paradoxically lowering colonic concentrations exactly when you need drug to keep working.

Oral Vancomycin: How and Why It Works

Oral vancomycin has been used against CDI since the late 1970s, when Tedesco et al. demonstrated its effectiveness in antibiotic-associated pseudomembranous colitis. Its pharmacology is what makes it so well suited to this infection, and what trips up so many patients and prescribers who confuse it with IV vancomycin.

Key principle: oral vancomycin is not absorbed from the gut. When swallowed, essentially none of it crosses the intestinal wall into the bloodstream. That sounds like a limitation, but it is actually the mechanism of action — all of the drug stays in the colon, where C. difficile lives and produces its toxins. Colonic concentrations reach levels many times higher than the minimum inhibitory concentration for C. diff, while systemic exposure remains negligible. This also explains why intravenous vancomycin has no effect on CDI. IV vancomycin is used to treat MRSA bacteremia and other systemic infections; it does not reach the colon in therapeutic concentrations. Prescribing IV vancomycin for CDI is a common and potentially dangerous error.

The standard dosing for non-severe CDI is 125 mg orally four times daily for 10 days. For severe or complicated CDI, the dose is increased to 500 mg four times daily, sometimes combined with IV metronidazole when ileus prevents reliable colonic drug delivery. Side effects of oral vancomycin are minimal because so little reaches the bloodstream — occasional nausea is the most common complaint. The concern about systemic ototoxicity and nephrotoxicity that applies to IV vancomycin does not apply here.

Generic oral vancomycin capsules are now widely available, which has substantially reduced cost. The branded formulation (Vancocin) was historically expensive, creating barriers to access that have largely been resolved. Vancomycin oral solution can be compounded from the IV formulation when capsules are unavailable — a useful option for patients with feeding tubes.

Fidaxomicin (Dificid): The Gut-Sparing Alternative

Fidaxomicin (brand name Dificid) is a macrocyclic antibiotic with a narrower spectrum than vancomycin, and that narrowness is its most important feature. It kills C. difficile effectively while sparing most of the beneficial anaerobes — particularly Bacteroides species — that help keep C. diff from returning after treatment ends.

Standard dosing is 200 mg orally twice daily for 10 days. Like oral vancomycin, fidaxomicin stays in the gut with minimal systemic absorption, achieving very high colonic concentrations. The OPCDT-10 trial (Louie et al., NEJM 2011) and the European/Canadian/US trial (Cornely et al., Lancet Infect Dis 2012) both demonstrated that fidaxomicin is non-inferior to vancomycin for initial clinical cure — approximately 88% versus 86% cure rates across both studies. But the recurrence data told a much more compelling story.

For non-NAP1/BI/027 strains (the majority of CDI cases outside major outbreaks), fidaxomicin reduced recurrence from approximately 25% with vancomycin down to 15% — a 40% relative reduction. In patients who have already had one CDI episode and are at high recurrence risk, that difference is meaningful. The mechanism is thought to be preservation of colonization resistance: by sparing Bacteroides and other commensals, fidaxomicin allows the gut flora to re-establish a competitive barrier against C. diff after treatment ends.

The 2021 IDSA/SHEA focused update places fidaxomicin as the preferred agent over vancomycin for initial non-severe CDI when cost and availability allow. The main limitation is cost — fidaxomicin remains expensive without generic availability, and some insurance plans require prior authorization. It is also less effective than vancomycin against the hypervirulent NAP1/BI/027 ribotype 027 strain, which produces higher spore loads; for confirmed NAP1 outbreaks, vancomycin remains the preferred choice.

Tapering and Pulsed Vancomycin for Recurrent CDI

Recurrent CDI poses a fundamentally different problem than initial infection. The pathogen is not antibiotic-resistant in the traditional sense — C. diff remains susceptible to vancomycin and fidaxomicin. The challenge is spores. C. difficile forms hardy spores that survive antibiotic treatment, then germinate into toxin-producing vegetative cells once the antibiotic is gone and colonic conditions are favorable. A standard 10-day course kills the vegetative bacteria but leaves spores intact, which can re-germinate within days to weeks of stopping treatment.

The pulsed/tapered vancomycin regimen was designed to work around this problem. Rather than maintaining continuous drug exposure that prevents germination, pulsing the antibiotic on alternating days creates windows that allow spores to germinate — at which point the next vancomycin dose kills the newly emerged vegetative cells before they can reproduce and toxin-produce at scale. A commonly used regimen for first recurrence when fidaxomicin is unavailable:

The evidence base for this regimen is primarily observational series rather than randomized trials, which means the precise optimal schedule remains uncertain. Nevertheless, clinical cure rates in recurrent CDI are substantially better with tapered/pulsed regimens than with a repeat standard 10-day course alone. The 2021 IDSA guidelines include tapered/pulsed vancomycin as an acceptable option for first recurrence, particularly when fidaxomicin is not available or affordable.

Bezlotoxumab (Zinplava): Blocking Toxin B to Prevent Recurrence

Bezlotoxumab takes a completely different approach to the CDI recurrence problem. Rather than targeting the bacteria, it targets the toxin. Bezlotoxumab is a fully human monoclonal antibody that binds to C. difficile Toxin B with high affinity, neutralizing it before it can attach to and destroy colonic epithelial cells. It does not treat the active infection — that still requires an antibiotic — but it significantly reduces the risk of recurrence in high-risk patients.

Bezlotoxumab is given as a single intravenous infusion of 10 mg/kg body weight, administered during the course of antibiotic treatment (typically around day 3–7). The FDA approved it in October 2016, based on the MODIFY I and MODIFY II trials (Wilcox et al., NEJM 2017). In those two pivotal trials, bezlotoxumab reduced the recurrence rate from approximately 26–28% with placebo to 17% — an absolute risk reduction of about 10 percentage points in patients receiving standard-of-care antibiotics. The number needed to treat to prevent one recurrence was approximately 10.

Bezlotoxumab is not for every CDI patient. Because it is expensive (approximately $4,500 per infusion) and most CDI episodes do not recur, the benefit is concentrated in patients with recognized risk factors for recurrence:

One caution: a subgroup analysis from MODIFY found a small increase in heart failure events in patients with a history of heart failure, though this did not reach statistical significance. Current guidelines recommend caution in patients with underlying congestive heart failure, and some prescribers avoid bezlotoxumab in patients with NYHA Class III–IV heart failure.

Rifaximin Chaser After Vancomycin

The rifaximin chaser strategy involves completing a standard oral vancomycin course and then immediately starting rifaximin — a minimally absorbed rifamycin antibiotic — for 20 additional days. The rationale is that rifaximin kills residual vegetative C. diff cells that survive the vancomycin course, buying time for colonization resistance to rebuild before spores can germinate successfully.

Rifaximin is active against C. diff at concentrations achievable in the colon, and unlike vancomycin, it also has some activity against rapidly dividing cells post-germination. A typical chaser regimen uses rifaximin 400 mg three times daily for 20 days immediately after the conclusion of vancomycin. Some protocols use lower doses (200 mg twice daily) for longer periods.

The evidence base is limited. A small randomized pilot trial (Johnson et al.) showed a trend toward reduced recurrence with rifaximin chaser, but the study was underpowered to reach statistical significance. Observational series have reported clinical success rates of 60–70% in recurrent CDI patients who failed other strategies. A significant concern is the emergence of rifaximin-resistant C. diff strains, particularly the NAP1/027 ribotype, which carries mutations in the rpoB gene conferring high-level rifamycin resistance. This limits the rifaximin chaser to patients with confirmed non-NAP1 strains in centers where ribotyping is available.

The 2021 IDSA guidelines do not formally recommend rifaximin chaser due to insufficient data and resistance concerns, but note it may be considered in selected patients with multiple recurrences who are not candidates for FMT or after FMT failure.

Managing First and Second Recurrences

Recurrent CDI is one of the most clinically frustrating problems in infectious disease. Recurrence rates after a first CDI episode run 15–25% with standard treatment. After a first recurrence, the risk of a second recurrence climbs to 40–60%. After a second recurrence, it exceeds 60%. Each recurrence damages the colonic microbiome further, making restoration of colonization resistance progressively harder.

First recurrence: The 2021 IDSA guidelines recommend fidaxomicin as the preferred agent if it was not used for the initial episode. When fidaxomicin was used initially or is not available, tapered/pulsed oral vancomycin is recommended rather than a repeat standard 10-day course. Adding bezlotoxumab during the antibiotic course should be considered in patients with one or more risk factors for recurrence (age, prior CDI, immunocompromise). A repeat 10-day standard vancomycin course without tapering or pulsing is explicitly discouraged for recurrent disease.

Second recurrence: For a second recurrence, the priority is breaking the recurrence cycle. Options include fidaxomicin (if not used previously), tapered/pulsed vancomycin, or vancomycin followed by rifaximin chaser in non-NAP1 cases. Bezlotoxumab should again be considered. However, at this point, fecal microbiota transplant (FMT) is increasingly the preferred intervention — it addresses the root cause (microbiome disruption) rather than just suppressing the pathogen.

Third or more recurrences: FMT is the treatment of choice. Clinical cure rates with FMT exceed 80–90% in patients who have failed multiple antibiotic courses, compared to 25–30% with additional antibiotics alone. The 2021 IDSA guidelines give FMT a strong recommendation for patients with three or more CDI episodes.

Surgical Management for Severe and Fulminant CDI

When CDI progresses to fulminant colitis — defined by hypotension, peritoneal signs, ileus, megacolon, or multiorgan failure — antibiotic treatment alone is frequently insufficient. The inflamed colon may deliver oral vancomycin poorly, and the pace of deterioration can be rapid. Mortality in fulminant CDI managed with antibiotics alone approaches 50–80%. Surgical intervention, while itself carrying substantial mortality, can be lifesaving.

Total abdominal colectomy with end ileostomy has historically been the definitive surgical procedure for fulminant CDI. The entire colon — the reservoir of C. diff and its toxins — is removed. Operative mortality ranges from 35% to 50%, reflecting the severity of the underlying illness and the poor baseline state of most patients who reach the operating room. Despite this high operative mortality, surgery improves survival compared to continued medical management in patients with peritoneal signs or shock. The key is timing: early surgical consultation and not waiting until the patient is moribund dramatically improves outcomes.

Diverting loop ileostomy with intraoperative colonic lavage offers a less morbid alternative that preserves the colon. Described by Neal et al. (Ann Surg 2011), this technique involves creating a diverting loop ileostomy to rest the colon, followed by intraoperative lavage of the colon with polyethylene glycol solution via a colonoscope, and then postoperative administration of vancomycin flushes (500 mg in 500 mL saline) through the ileostomy into the colon at 6-hour intervals. The Neal series demonstrated outcomes similar to colectomy with substantially lower morbidity and the ability to reverse the ileostomy once the infection resolved — something not possible after colectomy.

The choice between these approaches depends on the patient's surgical risk, the degree of colonic necrosis (perforation or necrosis mandate colectomy), and institutional experience. The ileostomy-lavage approach is most appropriate for patients without frank peritonitis or perforation who nonetheless require surgical decompression. All patients with fulminant CDI who are not improving on maximal medical therapy within 48–72 hours warrant urgent surgical consultation.

Key Research Papers

  1. Johnson S, Lavergne V, Skinner AM, et al. Clinical Practice Guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 Focused Update on Management of Clostridioides difficile Infection in Adults. Clin Infect Dis. 2021;73(5):e1029-e1044. PMID: 34164374
  2. Louie TJ, Miller MA, Mullane KM, et al. Fidaxomicin versus Vancomycin for Clostridium difficile Infection. N Engl J Med. 2011;364(5):422-431. PMID: 21288078
  3. Cornely OA, Crook DW, Esposito R, et al. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial. Lancet Infect Dis. 2012;12(4):281-289. PMID: 22321770
  4. Zar FA, Bakkanagari SR, Moorthi KM, Davis MB. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis. 2007;45(3):302-307. PMID: 17599306
  5. Wilcox MH, Gerding DN, Poxton IR, et al. Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection. N Engl J Med. 2017;376(4):305-317. PMID: 28121498
  6. Tedesco FJ, Gordon D, Fortson WC. Approach to patients with multiple relapses of antibiotic-associated pseudomembranous colitis. Lancet. 1978;2(8082):226-228. PMID: 78961
  7. Teasley DG, Gerding DN, Olson MM, et al. Prospective randomised trial of metronidazole versus vancomycin for Clostridium-difficile-associated diarrhoea and colitis. Lancet. 1983;2(8358):1043-1046. PMID: 6138597
  8. Neal MD, Alverdy JC, Hall DE, Simmons RL, Zuckerbraun BS. Diverting loop ileostomy and colonic lavage: an alternative to total abdominal colectomy for the treatment of severe, complicated Clostridium difficile associated disease. Ann Surg. 2011;254(3):423-429. PMID: 21865944
  9. Johnson S, Louie TJ, Gerding DN, et al. Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials. Clin Infect Dis. 2014;59(3):345-354. PMID: 24799326
  10. Maroo S, Lamont JT. Recurrent Clostridium difficile. Gastroenterology. 2006;130(4):1311-1316. PMID: 16618389

Back to Table of Contents

Connections

Back to Table of Contents